Keyword Connections

•  Ming Jiang

•  Serk In Park

•  Simon Hayward

Resources

• No matching connections

Communities

• No matching connections

Publications

• Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
  Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N, American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association
  (2010) CA Cancer J Clin 60: 194-201
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
  Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators
  (2010) N Engl J Med 363: 411-22
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
  Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M
  (2012) N Engl J Med 366: 2443-54
• Long-term functional outcomes after treatment for localized prostate cancer.
  Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF
  (2013) N Engl J Med 368: 436-45
• Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.
  Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Røder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC, COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative, Australian Prostate Cancer Bioresource, UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology, UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators, PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Kote-Jarai Z, Easton DF
  (2013) Nat Genet 45: 385-91, 391e1-2
• Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility.
  Gudmundsson J, Sulem P, Gudbjartsson DF, Blondal T, Gylfason A, Agnarsson BA, Benediktsdottir KR, Magnusdottir DN, Orlygsdottir G, Jakobsdottir M, Stacey SN, Sigurdsson A, Wahlfors T, Tammela T, Breyer JP, McReynolds KM, Bradley KM, Saez B, Godino J, Navarrete S, Fuertes F, Murillo L, Polo E, Aben KK, van Oort IM, Suarez BK, Helfand BT, Kan D, Zanon C, Frigge ML, Kristjansson K, Gulcher JR, Einarsson GV, Jonsson E, Catalona WJ, Mayordomo JI, Kiemeney LA, Smith JR, Schleutker J, Barkardottir RB, Kong A, Thorsteinsdottir U, Rafnar T, Stefansson K
  (2009) Nat Genet 41: 1122-6
• Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21.
  Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, Rybicki BA, Isaacs WB, Ingles SA, Stanford JL, Diver WR, Witte JS, Hsing AW, Nemesure B, Rebbeck TR, Cooney KA, Xu J, Kibel AS, Hu JJ, John EM, Gueye SM, Watya S, Signorello LB, Hayes RB, Wang Z, Yeboah E, Tettey Y, Cai Q, Kolb S, Ostrander EA, Zeigler-Johnson C, Yamamura Y, Neslund-Dudas C, Haslag-Minoff J, Wu W, Thomas V, Allen GO, Murphy A, Chang BL, Zheng SL, Leske MC, Wu SY, Ray AM, Hennis AJ, Thun MJ, Carpten J, Casey G, Carter EN, Duarte ER, Xia LY, Sheng X, Wan P, Pooler LC, Cheng I, Monroe KR, Schumacher F, Le Marchand L, Kolonel LN, Chanock SJ, Van Den Berg D, Stram DO, Henderson BE
  (2011) Nat Genet 43: 570-3
• Under pressure: stromal fibroblasts change their ways.
  Bierie B, Moses HL
  (2005) Cell 123: 985-7
• The Molecular Taxonomy of Primary Prostate Cancer.
  Cancer Genome Atlas Research Network
  (2015) Cell 163: 1011-25
• Autonomic nerve development contributes to prostate cancer progression.
  Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, Frenette PS
  (2013) Science 341: 1236361
• Cancer. Prostate cancer takes nerve.
  Isaacs JT
  (2013) Science 341: 134-5
• TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia.
  Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL
  (2004) Science 303: 848-51
• PSA screening and elderly men.
  Singer EA, Penson DF, Palapattu GS
  (2007) JAMA 297: 949; author reply 949-50
• MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL.
  Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, Vargo-Gogola TC, Begtrup JL, Peterson TE, Fingleton B, Shirai T, Matrisian LM, Futakuchi M
  (2005) Cancer Cell 7: 485-96
• mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice.
  Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mullholland DJ, Magnuson MA, Wu H, Sabatini DM
  (2009) Cancer Cell 15: 148-59
• Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition.
  Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, Ayala GE, Peterson LE, Ittmann M, Spencer DM
  (2007) Cancer Cell 12: 559-71
• Hepsin promotes prostate cancer progression and metastasis.
  Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V
  (2004) Cancer Cell 6: 185-95
• Synergistic and tunable human gene activation by combinations of synthetic transcription factors.
  Perez-Pinera P, Ousterout DG, Brunger JM, Farin AM, Glass KA, Guilak F, Crawford GE, Hartemink AJ, Gersbach CA
  (2013) Nat Methods 10: 239-42
• General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study.
  Penson DF, Feng Z, Kuniyuki A, McClerran D, Albertsen PC, Deapen D, Gilliland F, Hoffman R, Stephenson RA, Potosky AL, Stanford JL
  (2003) J Clin Oncol 21: 1147-54
• Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.
  Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, Ballentine Carter H, Costantino JP, Epstein JI, Godley PA, Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P, American Society of Clinical Oncology Health Services Committee, American Urological Association Practice Guidelines Committee
  (2009) J Clin Oncol 27: 1502-16
• Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE.
  Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA
  (2010) J Clin Oncol 28: 1069-74
• Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
  Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS
  (2016) J Clin Oncol 34: 2098-106
• Racial/Ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer.
  Johnson TK, Gilliland FD, Hoffman RM, Deapen D, Penson DF, Stanford JL, Albertsen PC, Hamilton AS
  (2004) J Clin Oncol 22: 4193-201
• Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension.
  Nazer B, Humphreys BD, Moslehi J
  (2011) Circulation 124: 1687-91
• Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
  Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N, American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association
  (2010) Circulation 121: 833-40
• Cardiology Patient Page. ABCDE Steps for Heart and Vascular Wellness Following a Prostate Cancer Diagnosis.
  Guan J, Khambhati J, Jones LW, Morgans A, Allaf M, Penson DF, Moslehi J
  (2015) Circulation 132: e218-20
• Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer.
  Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, Moslehi J
  (2016) Circulation 133: 537-41
• Urological cancer: walking the tightrope of survival and quality of life with ADT.
  Resnick MJ
  (2013) Nat Rev Clin Oncol 10: 307-8
• Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
  Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ
  (2002) J Natl Cancer Inst 94: 981-90
• PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
  Kirschner AN, Wang J, van der Meer R, Anderson PD, Franco-Coronel OE, Kushner MH, Everett JH, Hameed O, Keeton EK, Ahdesmaki M, Grosskurth SE, Huszar D, Abdulkadir SA
  (2015) J Natl Cancer Inst 107:
• Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data.
  Hadley J, Yabroff KR, Barrett MJ, Penson DF, Saigal CS, Potosky AL
  (2010) J Natl Cancer Inst 102: 1780-93